Defining The Role Of The 5-HT4 Receptor In The Brain, Behavior And Gut Abnormalities Resulting From In Utero SSRI Exposure
Abstract
Depression during pregnancy is common. Because untreated maternal depression during pregnancy is associated with negative psychiatric and gastrointestinal (GI) developmental outcomes in children, treatment is paramount. The safest and first-line therapy, selective serotonin reuptake inhibitors (SSRIs), however, also cause GI and psychiatric issues. Our laboratories have validated the first mouse model of perinatal SSRI exposure that demonstrates an impact of perinatal SSRI exposure on all four parts of the brain-gut-behavior-microbiome (BGBM)axis. Utilizing this model, we generated key evidence confirming that developmental SSRI (fluoxetine) exposure leads to long-lasting alterations in brain wiring, behavior (depression, anxiety), enteric nervous system (ENS) development, GI functions (constipation, altered intestinal epithelial growth) and the intestinal microbiome. Importantly, the BGBM abnormalities demonstrated in our model mimic those demonstrated in children exposed to SSRIs perinatally, making a translational in-depth analysis of the SSRI-BGBM axis interplay now feasible. Further, we have utilized this model to demonstrate that treatment with a serotonin 4 receptor (5-HT4R) antagonist, piboserod, during early development, rescues intestinal, behavioral and enteric microbiota phenotypes in mice exposed to SSRIs during the perinatal period.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2018
- Accession Number
- AD1055810
Entities
People
- Kara Margolis
Organizations
- Columbia University Irving Medical Center